AAAAAA

   
Results: 1-8 |
Results: 8
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer
Authors: Papadopoulos, KP Egorin, MJ Huang, M Troxel, AB Kaufman, E Balmaceda, CM Vahdat, LT Hesdorffer, CS
Citation: Kp. Papadopoulos et al., The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer, CANC CHEMOT, 47(1), 2001, pp. 45-50
Tandem transplantation in lymphoma
Authors: Papadopoulos, KP Noguera-Irizarry, W Hesdorffer, CS
Citation: Kp. Papadopoulos et al., Tandem transplantation in lymphoma, BONE MAR TR, 28(6), 2001, pp. 529-535
Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma
Authors: Moschella, F Maffei, A Catanzaro, RP Papadopoulos, KP Skerrett, D Hesdorffer, CS Harris, PE
Citation: F. Moschella et al., Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma, BR J HAEM, 114(2), 2001, pp. 444-457
CD34(+) cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer
Authors: Papadopoulos, KP Ayello, J Reiss, RF Troxel, A Kaufman, E Vahdat, LT Antman, KH Hesdorffer, CS
Citation: Kp. Papadopoulos et al., CD34(+) cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer, J HEMATH ST, 8(4), 1999, pp. 357-363
Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells
Authors: Papadopoulos, KP Hesdorffer, CS Suciu-Foca, N Hibshoosh, H Harris, PE
Citation: Kp. Papadopoulos et al., Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells, CLIN CANC R, 5(8), 1999, pp. 2089-2093
Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel
Authors: Lee, RT Oster, MW Balmaceda, C Hesdorffer, CS Vahdat, LT Papadopoulos, KP
Citation: Rt. Lee et al., Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel, ANN ONCOL, 10(10), 1999, pp. 1245-1247
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors
Authors: Papadopoulos, KP Balmaceda, C Fetell, M Kaufman, E Vahdat, LT Bruce, J Sisti, M Isaacson, S De LaPaz, R Savage, DG Troxel, A Antman, KH Hesdorffer, CS
Citation: Kp. Papadopoulos et al., A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors, J NEURO-ONC, 44(2), 1999, pp. 155-162
Translocation (4;15)(p16;q24): A novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blasticphase
Authors: Papadopoulos, KP Murty, VVV Lin, N Matsushima, A Riemer, E Rao, PH Nichols, GL
Citation: Kp. Papadopoulos et al., Translocation (4;15)(p16;q24): A novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blasticphase, CANC GENET, 111(1), 1999, pp. 18-20
Risultati: 1-8 |